Navigation Links
AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2,Data for Ozarelix, in BPH at Annual AUA Meeting

nificant and clinically meaningful efficacy in the treatment of LUTS secondary to BPH; - No statistically significant impact on quality of life or erectile function; and - Intramuscular 15 mg + 15 mg was the most effective regimen in this study. About Ozarelix and Partnerships

Ozarelix is a fourth generation luteinizing hormone-releasing hormone (LHRH) antagonist administered as a depot formulation for the treatment of benign and malign hormone-dependent diseases. It is currently in Phase 2b clinical trials for both BPH and prostate cancer.

In August 2004, AEterna Zentaris granted Spectrum Pharmaceuticals an exclusive license to develop and market ozarelix for all potential indications in North America and India, while AEterna Zentaris retains exclusive rights to the rest of the world. Spectrum will also receive 50% of any upfront and milestone payments, royalties and/or profits from sales of the product in Japan.

Furthermore, AEterna Zentaris recently granted Japanese rights for all potential oncology indications to Nippon Kayaku, a key player in the Japanese oncology market.

About Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate frequently occurring in men over the age of 50. The enlargement can result in the gradual squeezing of the urethra, resulting in increased frequency or difficulty in urinating. Enlargement of the prostate is controlled by testosterone. According to the National Institutes of Health, BPH affects more than 50% of men over the age of 60 and as many as 90% of men over the age of 70. Treatment options for BPH include surgery and medications to reduce the amount of tissue and increase the flow of urine. Current treatment options are inconvenient, leading to ineffective compliance and are only effective in roughly half of the patients treated. According to Decision Resource, in 2004, the total prevalence cases
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/31/2015)...  Boston Children,s Hospital physicians report the first ... their anatomy before undergoing high-risk brain procedures. The ... the brain,s blood vessels) that posed special treatment ... Journal of Neurosurgery: Pediatrics , the physicians ... resins to create custom, high-fidelity models of the ...
(Date:7/31/2015)... 31, 2015  Xcelience, a contract development and ... made a structured cash investment in Powdersize, a ... milling, micronization and powder size classification within the ... business while simultaneously adding a complete set of ... capabilities. "As we continue to ...
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
Breaking Medicine Technology:3D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
(Date:7/31/2015)... (PRWEB) , ... August 01, 2015 , ... Super Bowl 50 will emanate ... Football League’s biggest day each year is the Super Bowl. In the two weeks that ... place from the host venue. The 2016 Super Bowl game will mark the 50th time ...
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage ... also the first provider of Exilis non-surgical fat reduction in New York. Due ... attracted a large International clientele. Many patients travel to New York to get ...
(Date:7/31/2015)... Alexandria, VA (PRWEB) , ... July 31, 2015 ... ... Foundation) introduced its new store run by GoodThreads. The store can be accessed ... products and designs, many of which are customizable. The best part: whenever a ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Sculpted Contours Luxury ... CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in the United ... 2014 for treating the outer thighs. The original applicator required a 2 hour ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... Australia, April 20 Progen Pharmaceuticals Limited (ASX: PGL; ... that shows its epigenetic technology successfully inhibits tumor ... Progen,s collaborators at the 100th Annual American Association ... was effective in ,switching on, important anti-cancer genes ...
... with the power and influence to improve the healthcare ... to reform the nation,s healthcare system dominate Modern ... Healthcare for 2009. Among those making the list are ... Services Department; Nancy-Ann DeParle, director of the newly created ...
... - A national team of researchers led by Mayo Clinic ... more likely to have similar DNA changes or variants in ... have the cancer. , The findings, being presented at the ... an independent validation of an earlier European study that found ...
... Southern California have identified a new drug compound that ... without the negative side effects typically associated with Cox-2 ... to have a strong anti-tumor effect while also attacking ... tumor growth, according to data presented at the AACR ...
... Universal Health Realty Income Trust (NYSE: UHT ) ... C. Stein as a Trustee. Mr. Stein becomes the seventh ... Trustee. Mr. Stein, 50, is currently president and ... real estate company specializing in the acquisition, development, leasing and ...
... to Provide Free Counseling to Military Members, Veterans, and ... is honoring National Volunteer Week (April 19-25, 2009) with ... professionals to join the Give an Hour(TM) network to ... Hour(TM) is a nonprofit organization that has created a ...
Cached Medicine News:Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 2Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 3Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 4Health News:Health Reformers Dominate Magazine's List of the Top 25 Women in Healthcare 2Health News:Mayo Clinic-led researchers confirm gene variants associated with the most common adult leukemia 2Health News:USC researchers develop new drug to target tumor cells and blood vessels 2Health News:Give an Hour(TM) Honors National Volunteer Week with Call to Service 2
Gynecomastia Vest...
Male Compression Vest Binder...
Ideal for breast compression and contouring breast cups....
Ideal for breast compression, adjustable hook and eye front closure with adjustable shoulder straps....
Medicine Products: